264208-72-2

Basic information

• Product Name: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
• Synonyms: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;4-Chloro-7-[N-methylpiperidin-4-ylmethoxy]-6-methoxyquinazoline;4-Chloro-6-Methoxy-7-(4-Methyl-piperidin-1-ylMethoxy)-quinazoline;7-((1-Methylpiperidin-4-yl)Methoxy)-4-chloro-6-Methoxyquinazoline;4-chloro-6-Methoxy-7-[(1-Methyl-4-piperidinyl)Methoxy]-Quinazoline;Quinazoline,4-chloro-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
• CAS NO: 264208-72-2
• Molecular Formula: C₁₆H₂₀ClN₃O₂
• Molecular Weight: 321.806
• Mol File: 264208-72-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 446.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.221
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.90±0.10(Predicted)
• CAS DataBase Reference: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(264208-72-2)
• EPA Substance Registry System: 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline(264208-72-2)

Safety Data

• Hazardous Substances Data: 264208-72-2(Hazardous Substances Data)

Usage

Description

4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline is a quinazoline derivative with potential pharmacological properties. It is a chemical compound that has been studied for its potential use in treating various diseases, including cancer and inflammatory conditions. 4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline exhibits inhibitory effects on specific enzymes and receptors in the body, making it a valuable candidate for drug development. Its unique structure and properties also make it a promising candidate for further research and potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline is used as a potential therapeutic agent for the treatment of various diseases, such as cancer and inflammatory conditions. Its inhibitory effects on certain enzymes and receptors make it a valuable candidate for drug development.
Used in Drug Development:
4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline is used as a candidate for the development of new drugs targeting specific enzymes and receptors involved in the pathogenesis of various diseases. Its unique structure and properties contribute to its potential as a promising therapeutic agent.
Used in Research:
4-Chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline is used as a subject of research to further explore its pharmacological properties and potential therapeutic applications. Its unique structure and properties make it an interesting candidate for studying the mechanisms of action and potential synergistic effects with other compounds in the treatment of various diseases.

Upstream product

• 166815-96-9 N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine 
• 20691-89-8 1-methyl-4-piperidinemethanol 
• 263400-68-6 4-chloro-6-methoxy-quinazolin-7-ol 
• 869475-52-5 C₉H₇FN₂O₂ 
• 338992-29-3 6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one 
• 906565-52-4 methyl 3-methoxy-4-(1-tert-butyloxycarbonylpiperidin-4-ylmethoxy)benzoate 
• 906565-53-5 methyl 5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate 
• 635678-10-3 methyl 2-amino-5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 635678-09-0 methyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 264208-69-7 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3,4-dihydroxyquinazolin-4-one 
• 193002-25-4 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one 

Downstream Products

• 1356000-45-7 C₂₉H₃₁FN₆O₃ 
• 1356000-47-9 C₂₉H₃₀F₂N₆O₃ 
• 443913-73-3 vandetanib 

Relevant articles and documents

QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF

Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I

Anilinoquinazoline inhibitors of the RET kinase domain - Elaboration of the 7-position

We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging.

A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines

A novel strategy to prepare 4-anilinoquinazoline derivatives based on the oxidation of the quinazoline ring is described. Quinazoline oxidation has been investigated and improved, thus leading to an efficient and high yielding method to quinazolin-4(3H)-ones. Efficiency of this approach has been evaluated synthesizing four well known tyrosine kinase inhibitors and comparing the obtained yields with those achievable through conventional synthetic methods.